Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +45.36%
#3 ADO Protocol ADO Protocol +38.91%
#4 Prom Prom +34.97%
#5 Pons Pons +33.94%
#6 TENDIES TENDIES +31.01%
#7 Collector Crypt Collector Crypt +28.01%
#8 StonkBroker StonkBroker +26.08%
#9 Collect on Fanable Collect on Fanable +20.42%
#10 Cysic Cysic +20.13%
Coin of the day
GEKKO GEKKO
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Xvivo Perfusion AB (publ) Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ)

XVIVO
Rangering i aksjer #9727
Xvivo Perfusion AB (publ) is a medical technology company that creates and... Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
Aksjekurs
$30.43
Sist synkronisert: 2026-08-28
Markedsverdi
$958.38M
Endring (1 dag)
-3.95%
Endring (1 år)
71.66%
Land
SE
Handel Xvivo Perfusion AB (publ) (XVIVO)

Kategori

Healthcare
P/E-forhold for Xvivo Perfusion AB (publ) (XVIVO)
P/E-forhold per 2026 TTM: 0
Ifølge Xvivo Perfusion AB (publ) sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Xvivo Perfusion AB (publ) fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Siemens Healthineers AG Siemens Healthineers AG
Siemens Healthineers AG
SHL.DE
 - -
DE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.